Center for Molecular Medicine and Immunology

Rosalyn D Blumenthal

David M Goldenberg

Michael K Samoszuk

Malik Juweid

Rita Alisauskas

Walter Lew

Zhiliang Ying

The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose. Measured levels of one or more cytokines in a patient subjected to cytotoxic therapy, relative to a normal population, may be used to determine the dose of a hematopoietic cytokine to be administered to the patient.

Method of determining cytokine dosage for improving myelosuppressive state

The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose.

Method of evaluating myelosuppressive state

Method of determining cytokine dosage for myelosuppressive state

Kits for detecting and treating endometriosis are provided, which contain a targeting molecule comprising an eosinophil peroxidase-binding component. Methods of detecting and treating endometriosis using eosinophil peroxidase-specific targeting molecules are also provided Targeting molecules comprise an eosinophil peroxidase-binding component and an accessory component; the accessory component comprising an agent conferring detectability or a therapeutic effect.

Method of detecting endometriosis

Growing community of inventors

Belleville, NJ, United States of America

Rosalyn D Blumenthal